Navigation Links
Advances in personalized medicine for lung cancer
Date:4/18/2012

Lugano-CH/Aurora-US-CO/Geneva-CH, 18 April 2012 -- Several new studies that may help doctors tailor lung cancer treatment to the characteristics of individual patients and of their tumors are being presented at the 3rd European Lung Cancer Conference in Geneva.

"A major goal of lung cancer treatment is to tailor the treatment to the individual," says Dr Fiona Blackhall from The Christie NHS Foundation Trust in Manchester, UK. "The studies that will be presented at ELCC 2012 are important practical steps to achieving this in the clinic. Methods ranging from convenient blood-based molecular tests, detailed genetic analysis of tumors and functional imaging techniques have been applied in patient populations receiving a range of treatments. These findings provide impetus to continue developing a personalized medicine approach to lung cancer with the overall aim of selecting the most effective treatment for the individual."

Proteins provide clues to outcomes

An international group of researchers report promising results with a test that may identify patients likely to benefit from first-line therapy with a particular drug combination.

Dr Oliver Gautschi from the Swiss Group for Clinical Cancer Research (SAKK), and collaborators from The Netherlands and the US company developing the test, conducted a retrospective analysis of two phase-II trials with a serum proteomic classifier called VeriStrat. Their aim was to evaluate the prognostic value of the test in patients with advanced non-small cell lung cancer receiving first-line treatment with bevacizumab and erlotinib.

VeriStrat uses mass spectrometry to measure proteins in pre-treatment blood and assigns a result that correlates with outcome from treatment with a class of drugs known as EGFR inhibitors, which includes erlotinib and gefitinib. The test was initially developed and validated in patients who had already been treated with chemotherapy, and who then recei
'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Page: 1 2 3 4 5

Related biology news :

1. Annual Bibliography of Significant Advances in Dietary Supplement Research 2007
2. New book includes advances in the science and practice of transfusion and transplantation
3. State fund advances titanium powder research, 9 other Iowa State projects
4. Evolution and climate change research advances at Rutgers-Camden
5. Iowa Power Fund advances researcher’s long quest for efficient solar power
6. Salient Stills Notches Significant Advances in Profitability, Diversity of Sales and Customers, and Video Forensics Technology in 2008
7. Olympus advances technology for laparo-endoscopic single-site surgery
8. New hope for advances in treating malaria
9. Using combinatorial libraries to engineer genetic circuits advances synthetic biology
10. Advances in lung cancer research announced at conference
11. JDRF-funded research advances potential for regeneration as a possible cure for type 1 diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)... of patients with undiagnosed, suspected genetic conditions, a certain ... higher molecular diagnostic yield than traditional molecular diagnostic methods, ... The study is being released to coincide with the ... sequencing, which sequences the protein­coding region of the genome ... in a cell or organism), has been rapidly applied ...
(Date:10/16/2014)... war on the human body. Battles are won, ... pancreatic cancer, this stalemate—known as tumor dormancy—can last ... a phenomena that is poorly understood. , ... of Salvatore Torquato, a Professor of Chemistry at ... tumor dormancy and the switch to a malignant ...
(Date:10/16/2014)... infections and worldwide claims the lives of 160,000 ... University have succeeded in developing a promising vaccination ... , Xavier Saelens (VIB/UGent): "We discovered a new ... development of a novel approach to vaccination against ... small children and elderly people." , RSV: ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Modeling tumor dormancy 2New perspectives for development of an RSV vaccine 2
... National Oceanic and Atmospheric Administration, and the co-trustees for ... announced today they have started the injury assessment and ... a legal process to determine the type and amount ... to natural resources and their human uses as a ...
... Troy, N.Y. The purification of drug components ... is particularly true of drugs that utilize proteins, which ... impurities. Scientists within the Center for Biotechnology and Interdisciplinary ... magnetic resonance (NMR) to understand and improve an important ...
... The National Institute of Neurological Disorders and Stroke (NINDS), ... two new sites as part of the Morris K. Udall ... grants will provide a five-year investment totaling more than $16 ... for Medical Research in Manhasset, N.Y. NINDS ...
Cached Biology News:Resource restoration planning process begins for BP/Deepwater Horizon oil spill 2Resource restoration planning process begins for BP/Deepwater Horizon oil spill 3Purifying proteins: Rensselaer researchers use NMR to improve drug development 2Purifying proteins: Rensselaer researchers use NMR to improve drug development 3NINDS awards new Udall Centers for Parkinson's Disease Research 2NINDS awards new Udall Centers for Parkinson's Disease Research 3
(Date:10/19/2014)... October 20, 2014 OCTOBER ... Meeting (ABIM). ABIM will take place ... information about ABIM 2014 is now available ... Delegates representing companies and organizations from all ... obtain information on the latest products and ...
(Date:10/19/2014)... The Asian Automatic patient billing report defines and segments ... revenue. The Automatic patient billing market in Asia is ... at a developing CAGR of 7.2% from 2013 to ... Automatic patient billing market, to get an idea of ... of the segmentation of this market in the same ...
(Date:10/19/2014)... The Asian Orthopedic braces and support systems ... analysis and forecast of revenue. The Orthopedic braces and support ... $416.5 million by 2018, at a developing CAGR of 4.4% ... the Asian Orthopedic braces and support systems market, to get ... a glimpse of the segmentation of orthopedic braces and support ...
(Date:10/18/2014)... The “Human Insulin Market- by ... Premixed), Modern Human Insulin (Rapid Acting, Long Acting, ... Tresiba, Others) - Forecast to 2018” provides a ... opportunities, current market trends, and strategies impacting the ... and forecasts of the revenue and share analysis. ...
Breaking Biology Technology:The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 2The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 5
... Kevin W. Sharer, chairman and chief executive officer of Amgen ... plan to retire from the Company at the end of ... an orderly transition process, Sharer will step down as CEO ... Company,s Board of Directors until December 31, 2012, at which ...
... OAKS, Calif., Dec. 15, 2011  Amgen (NASDAQ: AMGN ... $0.36 per share dividend for the first quarter of 2012. ... the previous two quarters. The dividend will be paid on ... the close of business on Feb. 15, 2012.  ...
... 15, 2011 Prolong Pharmaceuticals today announced ... spearhead the firms, engineering and facilities planning ...   Having previously directed the construction of the ... Grange Castle facility in Dublin, Ireland, Flachmeyer is ...
Cached Biology Technology:Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012 2Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012 3Amgen Announces 2012 First Quarter Dividend 2Amgen Announces 2012 First Quarter Dividend 3Prolong's Large Scale Manufacturing of Sickle Cell Product to be Headed by Industry Veteran 2